|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Interaction between root growth and mineral nutrition显示文摘 | SATTELMACHER B GERENDAS J BAGDADY N H | 1993 | Environmental and experimental botany1993，33，1： | 1 |
| 2 | Lacrimal gland of the camel(Camelus dromedarius)显示文摘 | AWKATI A AL BAGDADI F | 1971 | Am J Vet Res1971，32，3： | 1 |
| 3 | Assessing safety critical braking events in naturalistic driving studies显示文摘 | Bagdadi O | 2013 | TranspRes Part F: Traffic Psychology and Behaviour2013，16，： | 1 |
| 4 | Interaction between root growth and mineral nutrition显示文摘 | Sattelmacher B Gerendas J Thoms K Brück H Bagdady NH | | 0，，： | 1 |
| 5 | 卵巢移行细胞癌:一例报道与文献复习(英文)显示文摘Transitional cell carcinoma(TCC)of the ovary is a rare and recently recognized subtype of ovarian epithelial cancer.We presented the first case report from our Institute(Sheri Kashmir Instiute of Medical Sciences,Srinagar,India),which was initially misdiagnosed as stromal cell carcinoma(granulosa cell tumour),and on review of histopathology with immunohistochemistry,the diagnosis of TCC of the ovary was established.The aim of this article was to describe the typical case of primary TCC of the ovary and to review the literature for information on TCC management. | Sheikh Aijaz Aziz Abdul Rashid Lone Mohmad Hussain Mir Sumyra Khursheed Qadri Arif Nabi Bhat Farhana Siraj Bagdadi Mir Muzaffar Bashir Sanjeed Ahmed | 2013 | The Chinese-German Journal of Clinical Oncology2013，12，9： | 0 |
| 6 | Real-life multi-center retrospective analysis on nivolumab in difficult-to-treat patients with advanced hepatocellular carcinoma显示文摘BACKGROUND Hepatocellular carcinoma(HCC)is one of the leading causes of cancer-related death worldwide.The landscape of the systemic treatment for advanced HCC is changing quickly,and recently,the standard of care became either atezolizumab plus bevacizumab or tremelimumab plus durvalumab in the single tremelimumab regular interval durvalumab regimen.Nivolumab monotherapy has proven to be effective sometimes for advanced HCC and could be a valuable treatment option for patients outside current treatment indications and reimbursement criteria for the standard of care.This is a particular population of interest.AIM To evaluate the real-world effectiveness of nivolumab monotherapy in patients with advanced HCC who are not eligible for other treatment.METHODS We conducted a retrospective,multicentric study including 29 patients with advanced HCC from 3 Belgian tertiary hospitals.All patients had had prior chemotherapy or were intolerant or ineligible for treatments.All study subjects received nivolumab 3 mg/kg in monotherapy,administered once every two weeks intravenously.Treatment continued until disease progression,severe adverse events or death.Data were retrieved from patients'medical records.The outcome parameters such as radiological response according to response evaluation criteria in solid tumors(RECIST)criteria,the biological response through the evolution of the alpha-fetoprotein(AFP)level,and clinical response considering both the Child–Pugh(CP)score and the World Health Organization(WHO)performance status(PS)were reported.A safety profile was also reported.Statistical analysis was performed using the SPSS Statistics 27 statistical software package.RESULTS The radiological overall response rate(defined as complete or partial response according to the immune RECIST and modified RECIST criteria)to nivolumab monotherapy was 24.1%.The biological overall response rate(defined as a decrease of≥25%in AFP blood level)was 20.7%.Radiological and biological responses were significantly associated both with each other(P<0.001)and with overall survival(P<0.005 for radiological response and P<0.001 for biological response).Overall survival was 14.5 mo(+/-2.1),and progression-free survival was 10.9 mo(+/-2.3).After 4 mo of treatment,78.3%of patients remained clinically stable or even showed improvement in WHO PS.Grade 3 adverse events occurred in 17.2%of patients,none had grade 4 adverse events,and no patients ceased nivolumab due to adverse events.CONCLUSION Nivolumab monotherapy is a good treatment choice in frail patients with HCC who are ineligible for the standard of care or other validated systemic treatments. | Nika De Wilde Luisa Vonghia Sven Francque Thomas De Somer Ali Bagdadi Eva Staub Jasper Lambrechts Ana-Maria Bucalau Gontran Verset Christophe Van Steenkiste | 2022 | World Journal of Hepatology2022，14，8： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员